{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:38:28Z","timestamp":1780583908225,"version":"3.54.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are many cytokines involved in the pathogenesis of osteoporosis. So far IL-33 involvement in osteoporotic patients has not yet been studied. IL-33 is a pro-inflammatory cytokine which mediates several immune functions; its involvement in a wide range of diseases, such as atopic dermatitis, asthma, and rheumatoid arthritis, is now emerging. In view of the crucial role of this cytokine in inflammation and bone remodeling, we measured IL-33 levels in the serum of postmenopausal women with osteoporosis. In 50 postmenopausal osteoporotic patients and 28 healthy postmenopausal control women, serum\u00a0IL-33 levels were measured by enzyme linked immunosorbent assay. In both patients and controls\u00a0the bone mineral density (BMD) was measured by double-energy X-ray absorptiometry (DXA). Vitamin D, calcium, alkaline phosphatase (ALP), parathyroid hormone (PTH)\u00a0serum levels, as well as bone turnover markers, such as C-terminal telopeptide of type 1 collagen (CTX) and N-terminal propeptide of type 1 procollagen (P1NP) were also evaluated. In postmenopausal osteoporotic women IL-33 levels were significantly lower compared to healthy controls (3.53\u2009\u00b1\u20092.45 vs. 13.72\u2009\u00b1\u20095.39\u2009pg\/ml; P\u2009=\u20090.009) and positively correlated respectively\u00a0with serum PTH (rho\u2009=\u20090.314; P\u2009=\u20090.026) and P1NP (rho\u2009=\u20090.373; P\u2009=\u20090.011) levels, while a statistically significant inverse correlation was observed between serum IL-33 and CTX levels (rho\u2009=\u2009\u22120.455; P\u2009=\u20090.002). Our results thus suggest that IL-33 represents an important bone-protecting cytokine which may be of therapeutic benefit in treating bone resorption.<\/jats:p>","DOI":"10.1038\/s41598-019-40212-6","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T11:04:07Z","timestamp":1551956647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Interleukin-33 serum levels in postmenopausal women with osteoporosis"],"prefix":"10.1038","volume":"9","author":[{"given":"Lia","family":"Ginaldi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4253-1312","authenticated-orcid":false,"given":"Massimo","family":"De Martinis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Saitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Maddalena","family":"Sirufo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Casciaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fedra","family":"Ciccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"40212_CR1","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nri.2016.95","volume":"16","author":"FY Liew","year":"2016","unstructured":"Liew, F. Y. et al. Interleukin-33 in health and disease. Nat Rev Immunol 16, 676\u2013689 (2016).","journal-title":"Nat Rev Immunol"},{"key":"40212_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.coi.2014.03.004","volume":"28","author":"DO Villarreal","year":"2014","unstructured":"Villarreal, D. O. & Weiner, D. B. Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 28, 102\u2013106 (2014).","journal-title":"Curr Opin Immunol"},{"key":"40212_CR3","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.immuni.2015.06.006","volume":"42","author":"AB Molofsky","year":"2015","unstructured":"Molofsky, A. B., Savage, A. & Locksley, R. M. Interleukin-33 in tissue homeostasis, injury and inflammation. Immunity 42, 1005\u20131019 (2015).","journal-title":"Immunity"},{"key":"40212_CR4","doi-asserted-by":"publisher","unstructured":"Demyanets, S. et al. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. Plos One 9 https:\/\/doi.org\/10.1371\/journal.pone.0095055 (2014).","DOI":"10.1371\/journal.pone.0095055"},{"key":"40212_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/imm.12174","volume":"141","author":"C Pei","year":"2014","unstructured":"Pei, C. et al. Emerging role of interleukin-33 in autoimmune diseases. Immunology 141, 9\u201317 (2014).","journal-title":"Immunology"},{"key":"40212_CR6","first-page":"14935","volume":"8","author":"R Li","year":"2015","unstructured":"Li, R. et al. Interleukin-33 and receptor ST2 as indicators in patients with asthma: a meta-analysis. Int J Clin Exp Med 8, 14935\u201314943 (2015).","journal-title":"Int J Clin Exp Med"},{"key":"40212_CR7","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1016\/j.humimm.2013.06.029","volume":"74","author":"WD Xu","year":"2013","unstructured":"Xu, W. D. et al. IL-33 in rheumatoid arthritis: Potential role in pathogenesis and therapy. Hum Immunol 74, 1057\u20131060 (2013).","journal-title":"Hum Immunol"},{"key":"40212_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.cyto.2011.12.010","volume":"58","author":"Z Xiangyang","year":"2012","unstructured":"Xiangyang, Z. et al. Increased levels of interleukin-33 associated with bone erosion and interstitial lung diseases in patients with rheumatoid arthritis. Cytokine 58, 6\u20139 (2012).","journal-title":"Cytokine"},{"key":"40212_CR9","doi-asserted-by":"publisher","unstructured":"Miller, A. M. Role of IL-33 in inflammation and disease. J Inflamm 8, (1), https:\/\/doi.org\/10.1186\/1476-9255-8-22 (2011).","DOI":"10.1186\/1476-9255-8-22"},{"key":"40212_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/nrrheum.2014.219","volume":"11","author":"H Takayanagi","year":"2015","unstructured":"Takayanagi, H. Osteoimmunology in 2014: Two-faced immunology-from osteogenesis to bone resorption. Nat Rev Rheumatol 11, 74\u201376 (2015).","journal-title":"Nat Rev Rheumatol"},{"key":"40212_CR11","doi-asserted-by":"publisher","first-page":"825","DOI":"10.7150\/ijms.5180","volume":"9","author":"R Zhao","year":"2012","unstructured":"Zhao, R. Immune regulation of osteoclast function in postmenopausal osteoporosis: a critical interdisciplinary perspective. Int J Med Sci 9, 825\u2013832 (2012).","journal-title":"Int J Med Sci"},{"key":"40212_CR12","doi-asserted-by":"publisher","first-page":"3754","DOI":"10.2174\/0929867323666160907162546","volume":"23","author":"L Ginaldi","year":"2016","unstructured":"Ginaldi, L. & De Martinis, M. Osteoimmunology and beyond. Curr Med Chem 23, 3754\u20133774 (2016).","journal-title":"Curr Med Chem"},{"key":"40212_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/nyas.12969","volume":"1364","author":"R Pacifici","year":"2016","unstructured":"Pacifici, R. T cells, osteoblasts, and osteocytes: interacting lineages key for the bone anabolic and catabolic activities of parathyroid hormone. Ann NY Acad Sci 1364, 11\u201324 (2016).","journal-title":"Ann NY Acad Sci"},{"key":"40212_CR14","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1002\/jbmr.269","volume":"26","author":"J Schulze","year":"2011","unstructured":"Schulze, J. et al. Interleukin-33 is expressed in differentiated osteoblasts and blocks osteoclast formation from bone marrow precursor cells. J Bone Min Res 26, 704\u2013717 (2011).","journal-title":"J Bone Min Res"},{"key":"40212_CR15","doi-asserted-by":"publisher","first-page":"6097","DOI":"10.4049\/jimmunol.1003487","volume":"186","author":"MM Zaiss","year":"2011","unstructured":"Zaiss, M. M. et al. IL-33 shifts the balance from osteoclast to alternatively activated macrophage differentiation and protects from TNF-\u03b1-mediated bone loss. J Immunol 186, 6097\u20136105 (2011).","journal-title":"J Immunol"},{"key":"40212_CR16","doi-asserted-by":"publisher","unstructured":"Cordero da Luz, F. A. et al. The physiopathological role of IL-33: new highlights in bone biology and a proposed role in periodontal disease. Med Inflamm, https:\/\/doi.org\/10.1155\/2014\/342410 (2014).","DOI":"10.1155\/2014\/342410"},{"key":"40212_CR17","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/en.2010-1268","volume":"152","author":"H Saleh","year":"2011","unstructured":"Saleh, H. et al. Interleukin-33, a target of parathyroid hormone and oncostatin m, increases osteoblastic matrix mineral deposition and inhibits osteoclast formation in vitro. Endocrinology 152, 1911\u20131922 (2011).","journal-title":"Endocrinology"},{"key":"40212_CR18","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cyto.2010.11.021","volume":"53","author":"S Saidi","year":"2011","unstructured":"Saidi, S. et al. IL-33 is expressed in human osteoblasts, but has no direct effect on bone remodeling. Cytokine 53, 347\u2013354 (2011).","journal-title":"Cytokine"},{"key":"40212_CR19","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.bbrc.2011.11.088","volume":"417","author":"J Keller","year":"2012","unstructured":"Keller, J. et al. Transgenic overexpression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochem Biophys Res Commun 417, 217\u2013222 (2012).","journal-title":"Biochem Biophys Res Commun"},{"key":"40212_CR20","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1007\/s00018-010-0410-y","volume":"67","author":"SH Mun","year":"2010","unstructured":"Mun, S. H. et al. Interleukin-33 stimulates formation of functional osteoclasts from human CD14+ monocytes. Cell Mol Life Sci 67, 3883\u20133892 (2010).","journal-title":"Cell Mol Life Sci"},{"key":"40212_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.bbrc.2015.03.033","volume":"460","author":"H Kiyomiya","year":"2015","unstructured":"Kiyomiya, H. et al. IL-33 inhibits RANKL-induced osteoclast formation through the regulation of Blimp-1 and IRF-8 expression. Biochem Biophys Res Commun 460, 320\u2013326 (2015).","journal-title":"Biochem Biophys Res Commun"},{"key":"40212_CR22","doi-asserted-by":"crossref","first-page":"53366","DOI":"10.18632\/oncotarget.18411","volume":"8","author":"X Zhu","year":"2017","unstructured":"Zhu, X. et al. Dectin-1 signaling inhibits osteoclastogenesis via IL-33-induced inhibition of NFATc1. Oncotarget 8, 53366\u201353374 (2017).","journal-title":"Oncotarget"},{"key":"40212_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.joen.2014.11.017","volume":"41","author":"M Velickovic","year":"2015","unstructured":"Velickovic, M. et al. ST2 deletion increases inflammatory bone destruction in experimentally induced periapical lesions in mice. J Endod 2015 41, 369\u2013375, https:\/\/doi.org\/10.1016\/j.joen.2014.11.017 (2015).","journal-title":"J Endod 2015"},{"key":"40212_CR24","first-page":"373","volume":"79","author":"World Medical Association Declaration of Helsinki","year":"2001","unstructured":"World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Org 79, 373\u2013374 (2001).","journal-title":"Bull World Health Org"},{"key":"40212_CR25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(02)08761-5","volume":"359","author":"JA Kanis","year":"2002","unstructured":"Kanis, J. A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359, 1929\u20131936 (2002).","journal-title":"Lancet"},{"key":"40212_CR26","doi-asserted-by":"publisher","unstructured":"L\u00f3pez-Mej\u00edas, R. et al. Protective Role of the Interleukin 33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Rheumatoid Arthritis Patients. Plos One. 10, https:\/\/doi.org\/10.1371\/journal.pone.0143153 (2015).","DOI":"10.1371\/journal.pone.0143153"},{"key":"40212_CR27","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1128\/IAI.02908-14","volume":"83","author":"O Rostan","year":"2015","unstructured":"Rostan, O. et al. Crucial and Diverse Role of the Interleukin-33\/ST2 Axis in Infectious Diseases. Infect Immun 83, 1738\u20131748 (2015).","journal-title":"Infect Immun"},{"key":"40212_CR28","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/cbin.10249","volume":"38","author":"Y Mine","year":"2014","unstructured":"Mine, Y. et al. Involvement of ERK and p38 MAPK pathways on Interleukin-33-induced RANKL expression in osteoblastic cells. Cell Biol Int 38, 655\u2013662 (2014).","journal-title":"Cell Biol Int"},{"key":"40212_CR29","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.mce.2014.10.014","volume":"399","author":"DG Eeles","year":"2015","unstructured":"Eeles, D. G. et al. Osteoclast formation elicited by interleukin-33 stimulation is dependent upon the type of osteoclast progenitor. Mol Cell Endocrinol 399, 259\u2013266 (2015).","journal-title":"Mol Cell Endocrinol"},{"key":"40212_CR30","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/nrendo.2015.139","volume":"11","author":"RW Cheloha","year":"2015","unstructured":"Cheloha, R. W. et al. PTH receptor-1 signalling - mechanistic insights and therapeutic prospects. Nat Rev Endocrinol 11, 712\u2013724 (2015).","journal-title":"Nat Rev Endocrinol"},{"key":"40212_CR31","doi-asserted-by":"publisher","first-page":"6790","DOI":"10.1074\/jbc.M709909200","volume":"283","author":"LJ Raggatt","year":"2008","unstructured":"Raggatt, L. J. et al. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions. J Biol Chem 283, 6790\u20136798 (2008).","journal-title":"J Biol Chem"},{"key":"40212_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3109\/09513590.2014.975683","volume":"31","author":"J Zhang","year":"2015","unstructured":"Zhang, J. et al. Changes of serum cytokines-related Th1\/Th2\/Th17 concentration in patients with postmenopausal osteoporosis. Gynecol Endocrinol 31, 183\u2013190 (2015).","journal-title":"Gynecol Endocrinol"},{"key":"40212_CR33","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.molimm.2014.06.018","volume":"63","author":"R Saluja","year":"2015","unstructured":"Saluja, R. et al. The role of the IL-33\/IL-1RL1 axis in mast cell and basophil activation in allergic disorders. Mol Immunol 63, 80\u201385 (2015).","journal-title":"Mol Immunol"},{"key":"40212_CR34","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12865-015-0125-9","volume":"16","author":"L Ginaldi","year":"2015","unstructured":"Ginaldi, L. et al. Increased levels of interleukin 31 (IL-31) in osteoporosis. BMC Immunol 16, 60, https:\/\/doi.org\/10.1186\/s12865-015-0125-9 (2015).","journal-title":"BMC Immunol"},{"key":"40212_CR35","doi-asserted-by":"publisher","unstructured":"Liew, F. Y. IL-33: a Janus cytokine. Ann Rheum Dis 71 (Suppl 2), https:\/\/doi.org\/10.1136\/annrheumdis-2011-200589 (2012).","DOI":"10.1136\/annrheumdis-2011-200589"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40212-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40212-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:18:25Z","timestamp":1671261505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40212-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40212"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40212-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,7]]},"assertion":[{"value":"21 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"3786"}}